ALXO alxoncology.com Company Short-Term Debt

ALX Oncology - graphic logo of issuer ALXO

The stability of ALX Oncology Holdings (ALXO) is confirmed by the safety of evorpacept, which destroys tumors without harming erythrocytes. The business foundation relies on the blocking of the CD47 protein for targeted attacks, while patent protection of innovations provides potential for combination therapy. The short-term debt trend demonstrates financial dynamics, where the value of 0.00 describes the company's current level of obligations for the coming year.

ALXO ALX Oncology Holdings Inc. Short-Term Debt (07/04/2022 - 11/01/2026)

Analytical breakdowns and data insights for company ALX Oncology Holdings Inc. (ALXO)

- current quotes and average value forecast:
Price Chart ALX Oncology|ALXO - Average Forecast Price
- market capitalization data:
Market Value ALX Oncology Holdings|ALXO - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share ALX Oncology|ALXO - Total Stockholders' Equity|Market Capitalization to Book Value Ratio alxoncology.com|ALXO - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio ALX Oncology Holdings|ALXO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio ALX Oncology Holdings|ALXO - Aggregate Debt Obligations|Debts to Book Capitalization ALX Oncology Holdings|ALXO - Long-Term Debt Volume|Company Short-Term Debt ALX Oncology|Quick Liquidity alxoncology.com
- earnings and multiples data:
ALXO - Net Income
General company analysis:ALX Oncology (ALXO)
Flagship merchandise of alxoncology.com

For ALX Oncology (ALXO), which invests in establishing cancer therapy standards, the management of short-term liabilities determines the financial sustainability of prolonged R&D cycles. Analyzing this chart of current debt obligations, an investor assesses the repayment dynamics of promissory notes and loans, where a moderate reduction in debt confirms capital reliability, while a sharp contraction may signal a scaling back of the development of innovative inhibitor proteins.

Competitors of ALX Oncology Holdings

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings LYEL (lyell.com)|IPHA: Company Short-Term Debts|PYXS - Short-Term Debt Volume|Company Short-Term Debt Compugen Ltd|Company Current Liabilities IO Biotech Inc. (IOBT)|Company Short-Term Debt Sutro Biopharma, Inc. (STRO)|Company Current Liabilities minktherapeutics.com INKT|Werewolf Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Debts Immix Biopharma Inc. IMMX|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)